<?xml version="1.0" encoding="UTF-8"?>
<p id="Par23">Remdesivir (GS-5734), a nucleotide analogue inhibitor of the viral RNA-dependent RNA polymerase of SARS-CoV-2, reduces the time to recovery from a median of 15 days in patients treated with placebo to a median of 11 days in those treated with the drug [
 <xref ref-type="bibr" rid="CR38">38</xref>]. Although the study is still ongoing, the authors also found that mortality in the remdesivir group was lower than the placebo arm (7.1% versus 11.9%). Clinical trials are still ongoing to determine the efficacy of remdesivir [
 <xref ref-type="bibr" rid="CR38">38</xref>, 
 <xref ref-type="bibr" rid="CR39">39</xref>]. However, the intravenous formulation of the drug requiring refrigeration for storage may limit its extensive use in resource-limited settings. It is yet to be determined whether orally available compounds, such as favipiravir (originally used for influenza) or directly acting antivirals (used for hepatitis C infection), could provide any significant effects in patients with COVID-19 [
 <xref ref-type="bibr" rid="CR40">40</xref>].
</p>
